ZFIN ID: ZDB-FIG-140522-7
Nissim et al., 2014 - Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. Developmental Cell   28(4):423-437 Full text @ Dev. Cell
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Knockdown Reagents:
Anatomical Terms:
Stage Range: Protruding-mouth to Day 4
PHENOTYPE:
Fish:
Conditions:
Knockdown Reagents:
Observed In:
Stage Range: Protruding-mouth to Day 4

Fig. 2 PGE2 Affects Embryonic Pancreas Outgrowth (A) In situ hybridization for trypsin, an exocrine pancreas-specific marker, following exposure to dmPGE2 or Indo reveals that embryonic pancreas size is regulated by PGE2. dmPGE2 increases exocrine pancreas size (57.6% embryos with an enlarged pancreas; n = 38/66), whereas Indo diminishes exocrine pancreas size (70.6% embryos with a smaller pancreas; n = 36/51). Dorsal view. (B) FACS quantification of GFP+ exocrine pancreas cells in elastase:GFP embryos at 96 hpf following exposure to dmPGE2 or Indo. dmPGE2 increases and Indo decreases the relative number of exocrine pancreas cells. (Data are represented as mean ± SEM; ****significant across treatment groups, ANOVA, p < 0.0001.)

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
GFP zf578Tg control Day 4 exocrine pancreas IFL
zf578Tg chemical treatment: prostaglandin E2 Day 4 exocrine pancreas IFL
zf578Tg chemical treatment: indometacin Day 4 exocrine pancreas IFL
ins WT control Day 4 endocrine pancreas ISH
WT chemical treatment: prostaglandin E2 Day 4 endocrine pancreas ISH
WT chemical treatment: indometacin Day 4 endocrine pancreas ISH
prss1 WT control Protruding-mouth endocrine pancreas ISH
WT chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas ISH
WT chemical treatment: indometacin Protruding-mouth exocrine pancreas ISH
WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a control Protruding-mouth exocrine pancreas ISH
WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas ISH
WT + MO1-ptger2a + MO2-ptger2a control Protruding-mouth exocrine pancreas ISH
WT + MO1-ptger2a + MO2-ptger2a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas ISH
WT + MO1-ptger4a + MO2-ptger4a control Protruding-mouth exocrine pancreas ISH
WT + MO1-ptger4a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas ISH
WT + MO1-ptgs1 + MO2-ptgs1 control Protruding-mouth exocrine pancreas ISH
WT + MO1-ptgs1 + MO2-ptgs1 chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas ISH
WT + MO1-ptgs2a + MO2-ptgs2a control Protruding-mouth exocrine pancreas ISH
WT + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas ISH
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
WT chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas prss1 expression increased distribution, abnormal
Protruding-mouth exocrine pancreas increased size, abnormal
WT chemical treatment: indometacin Protruding-mouth exocrine pancreas prss1 expression decreased distribution, abnormal
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a control Protruding-mouth exocrine pancreas prss1 expression decreased distribution, abnormal
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas prss1 expression amount, ameliorated
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptger2a + MO2-ptger2a control Protruding-mouth exocrine pancreas prss1 expression decreased distribution, abnormal
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptger2a + MO2-ptger2a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas prss1 expression amount, ameliorated
Protruding-mouth exocrine pancreas size, ameliorated
WT + MO1-ptger4a + MO2-ptger4a control Protruding-mouth exocrine pancreas prss1 expression decreased distribution, abnormal
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptger4a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas prss1 expression amount, ameliorated
Protruding-mouth exocrine pancreas size, ameliorated
WT + MO1-ptgs1 + MO2-ptgs1 control Protruding-mouth exocrine pancreas prss1 expression decreased distribution, abnormal
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptgs1 + MO2-ptgs1 chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas prss1 expression amount, ameliorated
Protruding-mouth exocrine pancreas size, ameliorated
WT + MO1-ptgs2a + MO2-ptgs2a control Protruding-mouth exocrine pancreas prss1 expression decreased distribution, abnormal
Protruding-mouth exocrine pancreas decreased size, abnormal
WT + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas prss1 expression amount, ameliorated
Protruding-mouth exocrine pancreas size, ameliorated
npas4ls5; gz15Tg chemical treatment: prostaglandin E2 Day 4 exocrine pancreas cell increased amount, abnormal
npas4ls5; gz15Tg chemical treatment: indometacin Day 4 exocrine pancreas cell decreased amount, abnormal
zf578Tg chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas increased size, abnormal
Day 4 exocrine pancreas GFP expression increased distribution, abnormal
Day 4 exocrine pancreas increased size, abnormal
zf578Tg chemical treatment: indometacin Day 4 exocrine pancreas GFP expression decreased distribution, abnormal
Day 4 exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a control Protruding-mouth exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptger2a + MO1-ptgs2a control Protruding-mouth exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptger2a + MO1-ptgs2a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas size, ameliorated
zf578Tg + MO1-ptger4a + MO2-ptger4a control Protruding-mouth exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptger4a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas size, ameliorated
zf578Tg + MO1-ptgs1 + MO2-ptgs1 control Protruding-mouth exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptgs1 + MO2-ptgs1 chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas size, ameliorated
zf578Tg + MO1-ptgs2a + MO2-ptgs2a control Protruding-mouth exocrine pancreas decreased size, abnormal
zf578Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Protruding-mouth exocrine pancreas size, ameliorated
Acknowledgments:
ZFIN wishes to thank the journal Developmental Cell for permission to reproduce figures from this article. Please note that this material may be protected by copyright.

Reprinted from Developmental Cell, 28(4), Nissim, S., Sherwood, R.I., Wucherpfennig, J., Saunders, D., Harris, J.M., Esain, V., Carroll, K.J., Frechette, G.M., Kim, A.J., Hwang, K.L., Cutting, C.C., Elledge, S., North, T.E., and Goessling, W., Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth, 423-437, Copyright (2014) with permission from Elsevier. Full text @ Dev. Cell